Market Indices
Sector Heatmap
RNA — Atrium Therapeutics, Inc. Common Stock
NasdaqAtrium Therapeutics, Inc. Common Stock
- O
- 8.15
- H
- 8.33
- L
- 7.97
- V
- 500.33K
RNA — Latest News & Headlines
20 StoriesAtrium Therapeutics Announces $50 Million Private Placement - Stock Titan
Atrium Therapeutics Announces $50 Million Private Placement Stock Titan
Gene Silencing Biotech ADARx Makes Some Noise With $535M Stock Market Debut - MedCity News
Gene Silencing Biotech ADARx Makes Some Noise With $535M Stock Market Debut MedCity News
Novartis wagers almost $8B on a Chinese biotech’s RNA drugs - BioPharma Dive
Novartis wagers almost $8B on a Chinese biotech’s RNA drugs BioPharma Dive
Wave Life Sciences Aligns With FDA on Registrational Path for RNA Editing Therapy WVE-006 in AATD - BioPharm International
Wave Life Sciences Aligns With FDA on Registrational Path for RNA Editing Therapy WVE-006 in AATD BioPharm International
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - Zacks Investment Research
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation Zacks Investment Research
Novartis Stocks Stay Flat as $575 Million RNA Bet Opens $7.2 Billion Tail - Yahoo Finance
Novartis Stocks Stay Flat as $575 Million RNA Bet Opens $7.2 Billion Tail Yahoo Finance
Patients Remain Undetectable 96 Weeks After Stopping Bulevirtide - AJMC
Patients Remain Undetectable 96 Weeks After Stopping Bulevirtide AJMC
ADARx’s $446m IPO signals investor appetite for next-gen RNA therapeutics - BioXconomy
ADARx’s $446m IPO signals investor appetite for next-gen RNA therapeutics BioXconomy
Technical Reactions to RNA Trends in Macro Strategies - Stock Traders Daily
Technical Reactions to RNA Trends in Macro Strategies Stock Traders Daily
Camp4 Therapeutics (Nasdaq:CAMP) - Stock Analysis - Simply Wall Street
Camp4 Therapeutics (Nasdaq:CAMP) - Stock Analysis Simply Wall Street
Atrium Therapeutics Announces $50 Million Private Placement - themountaineer.com
Atrium Therapeutics Announces $50 Million Private Placement themountaineer.com
Atrium Therapeutics Secures $50 Million Private Placement to Advance RNA-Based Cardiology Pipeline - citybiz
Atrium Therapeutics Secures $50 Million Private Placement to Advance RNA-Based Cardiology Pipeline citybiz
PacBio Deepens AI Drug-Discovery Push With TychoBio Deal — PACB Stock Takes A Breather After 103% Rally - TradingView
PacBio Deepens AI Drug-Discovery Push With TychoBio Deal — PACB Stock Takes A Breather After 103% Rally TradingView
Avidity Biosciences misses HARBOR endpoint: analysts target RNA stock at USD 63.75 - AD HOC NEWS
Avidity Biosciences misses HARBOR endpoint: analysts target RNA stock at USD 63.75 AD HOC NEWS
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal - Yahoo Finance
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal Yahoo Finance
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal - Zacks Investment Research
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal Zacks Investment Research
FDA supports a one-year data check for possible faster approval of Wave's treatment. - Stock Titan
FDA supports a one-year data check for possible faster approval of Wave's treatment. Stock Titan
How Investors Are Reacting To Recursion Pharmaceuticals (RXRX) RNA Model Licensing Deal - Simply Wall Street
How Investors Are Reacting To Recursion Pharmaceuticals (RXRX) RNA Model Licensing Deal Simply Wall Street
Wave Life Sciences, Inc. (WVE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wave Life Sciences, Inc. (WVE) Stock Price, News, Quote & History Yahoo! Finance Canada
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price, News, Quote & History Yahoo! Finance Canada